<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7481143\results\search\testTrace\results.xml">
  <result pre="is the means to discover or to produce an effective" exact="treatment" post="against this global disease. Scientists from several areas in"/>
  <result pre="capacity, high levels of nucleotide substitutions, their efficiency in causing" exact="infection" post="in new hosts and interspecies transmission.12 HCoVs, such as"/>
  <result pre="SARS-CoV-2 spread are washing hands as many times as possible," exact="social distancing" post="and covering the face when coughing or sneezing.28 These"/>
  <result pre="and to maintain preventive behaviours against the virus dissemination.29 The" exact="diagnosis" post="of COVID-19 was rapidly implemented through the identification of"/>
  <result pre="molecular biology as well as available advances and technology. SARS-CoV-2" exact="infection" post="is generally detected by reverse transcriptaseâ€&quot;polymerase chain reaction (RT-PCR)"/>
  <result pre="direct the cell machinery to produce more viruses.33 A viral" exact="infection" post="is successful when the virus crosses the host cell"/>
  <result pre="crosstalk.55 Data from research conducted thus far indicate that the" exact="infection" post="caused by SARS-CoV-2 is not only capable of causing"/>
  <result pre="to a systemic compromise prompted by the virus once the" exact="treatment" post="has begun. Hence, it is possible to observe the"/>
  <result pre="or death.57 The incidence of the extreme form of the" exact="infection" post="is associated with cytokine storm syndrome, characterized by high"/>
  <result pre="to proteins coded by other CoVs. The results enabled the" exact="detection" post="of structural similarities to SARS-CoV, from which it was"/>
  <result pre="transcription, translation, protein synthesis, processing and modification, viral replication and" exact="infection" post="of the host. Significant functional proteins, 3CLpro, PLpro, helicases"/>
  <result pre="such as Remdesivir, which already shows great potential in the" exact="treatment" post="of COVID-19 infections. In addition, some non-structural proteins, including"/>
  <result pre="reinforced by studies by Jin et al.80 after the virtual" exact="screening" post="of N3 inhibitor. Results show that N3 (1) is"/>
  <result pre="stable covalent bond is formed between N3 and 3CLpro. High-throughput" exact="screening" post="(HTS) was applied to 10,000 drugs and drug candidates,"/>
  <result pre="had the strongest antiviral effects at a concentration of 10â€¯Î¼M" exact="treatment" post="in SARS-CoV-2 infected Vero cells. After plaque-reduction assay, the"/>
  <result pre="fluorine-carbon bond at 5-position. This compound is used in the" exact="treatment" post="of oesophageal cancer,82 stomach cancer,91 breast and colon cancer.92"/>
  <result pre="the European Union (EU) approved Baricitinib (10) as second-line oral" exact="treatment" post="for mild to severe active rheumatoid arthritis in adults"/>
  <result pre="of the important mechanisms of action of baricitinib in the" exact="treatment" post="of rheumatoid arthritis is the inhibition of the IL-6"/>
  <result pre="can lead the disease to progress and increase anaemia. Furthermore," exact="treatment" post="with Baricitinib can reactivate varicella-zoster, herpes simplex and Epstein-Barr"/>
  <result pre="Suggesting repurposing TBV to fight COVID-19 was prompted by virtual" exact="screening" post="to find drugs that act on viral Mpro. Among"/>
  <result pre="was given vancomycin and cefepime. As the symptoms worsened, intravenous" exact="treatment" post="with RDV was administered at day 7, and vancomycin"/>
  <result pre="clinical improvement, unfortunately details on the doses and duration of" exact="treatment" post="were not provided.135 After this first case, a clinical"/>
  <result pre="they were breathing ambient air or receiving oxygen support. The" exact="treatment" post="lasted 10â€¯days, patients were given 200â€¯mg intravenously on day"/>
  <result pre="inhibits the Human Herpesvirus and is also indicated in the" exact="treatment" post="of cytomegalovirus infections related to Acquired Immunodeficiency Syndrome (AIDS).138"/>
  <result pre="into ganciclovir. Using valganciclovir in its oral form enables clinical" exact="treatment" post="and makes patients more comfortable.141, 142, 143 The mechanism"/>
  <result pre="to the efficacy of treatment, clinical trials can validate the" exact="prevalence" post="of adverse effects related to the toxicity of TFV"/>
  <result pre="to proximal tubular cells. In spite of that, interrupting the" exact="treatment" post="is sufficient to improve adverse effects, which makes monitoring"/>
  <result pre="virus in children, generally combined with Interferon (INF). However, ribavirin" exact="treatment" post="presents undesirable adverse effects, like lowering of haemoglobin, which"/>
  <result pre="treatment, at 200â€¯Î¼g/ml or higher, reduced infectious virus below the" exact="detection" post="threshold of 13.7 TCID50/ml. Next, these drugs were tested"/>
  <result pre="would augment the activity of the other. In-vitro cell combined" exact="treatment" post="lowered the threshold at which a decrease in CPE"/>
  <result pre="the percentages of detectable viral RNA and time of the" exact="treatment" post="were similar in both groups. The total time of"/>
  <result pre="treatment were similar in both groups. The total time of" exact="treatment" post="was one day shorter for LPV/RTV. Also, gastrointestinal adverse"/>
  <result pre="interferon beta-1b and ribavirin could present better outcomes than the" exact="treatment" post="with LPV/RTV alone. The 127 adult patients were randomly"/>
  <result pre="respectively) every 12â€¯h. Both groups were medicated for 14â€¯days. The" exact="treatment" post="that combined the three drugs suppressed viral loads in"/>
  <result pre="throat, back of the oropharyngeal and faeces) after 8â€¯days of" exact="treatment" post="whereas the control group suppressed viral load after 12â€¯days"/>
  <result pre="whereas the control group suppressed viral load after 12â€¯days of" exact="treatment" post="in average. The triple combination also achieved relief of"/>
  <result pre="a 71-year-old woman in China presented positive results for combined" exact="treatment" post="with oseltamivir and LPV/RTV, testing negative for viral infection"/>
  <result pre="presented positive results for combined treatment with oseltamivir and LPV/RTV," exact="testing" post="negative for viral infection after 48â€¯h. A different study"/>
  <result pre="combined treatment with oseltamivir and LPV/RTV, testing negative for viral" exact="infection" post="after 48â€¯h. A different study by Chen et al.140"/>
  <result pre="24â€¯h after the infection, the infected cells were scored by" exact="immunofluorescence" post="analysis with an antibody specific for the viral N"/>
  <result pre="CsA to increase ACE2 shedding and, consequently, to augment SARS-CoV-2" exact="infection" post="by increment the ACE2 upregulation.200 Furthermore, the CsA has"/>
  <result pre="MERS-CoV and SARS-CoV.202 Recent investigations have suggested teicoplanin as alternative" exact="treatment" post="for COVID-19 after an in-vitro assay achieved IC50 value"/>
  <result pre="against COVID-19. This drug is an antiviral used in the" exact="treatment" post="of HIV-1 infections. It provides a great genetic barrier"/>
  <result pre="drug might perform its potentially beneficial immunomodulatory role as a" exact="treatment" post="alternative for COVID-19 pneumonia. In addition, the use of"/>
  <result pre="for COVID-19 pneumonia. In addition, the use of imatinib as" exact="treatment" post="appears to be reasonable from an economic point of"/>
  <result pre="in order to elect him as candidate drug in the" exact="treatment" post="of COVID-19. 5.6.3 Nitazoxanide (NTZ) Synthesized for the first"/>
  <result pre="molecules with a quinoline group have been widely investigated as" exact="treatment" post="for the new coronavirus (SARS-CoV-2), such as Chloroquine (CQ)"/>
  <result pre="Melatonin (42). The mechanism of action of CQ for anti-malarial" exact="treatment" post="is not entirely clear, but the interference with the"/>
  <result pre="show significant difference when the drugs were used either in" exact="isolation" post="or combined or when no medication was administered. An"/>
  <result pre="7) is an FDA-approved broad-spectrum antiparasitic agent used in the" exact="treatment" post="of tropical diseases, such as onchocerciasis, lymphatic filariasis, strongyloidiasis"/>
  <result pre="proteins have revealed a potential role for IMP Î±/Î²1 during" exact="infection" post="in signal-dependent nucleocytoplasmic shutting of the SARS-CoV nucleocapsid protein.272"/>
  <result pre="al.274 conducted in-vitro experiments on Vero-hSLAM cells. Two hours after" exact="infection" post="with SARS-CoV-2, a single 5â€¯Î¼M dose of ivermectin was"/>
  <result pre="in Russia and for 14â€¯years in China as prophylaxis and" exact="treatment" post="of influenzas A and B. Arbidol has become the"/>
  <result pre="activity. Data also show that Arbidol not only mitigates viral" exact="infection" post="but also interferes with the release of intracellular vesicles"/>
  <result pre="mechanism involved in the antiviral action of emetine both in" exact="isolation" post="and combined to other drugs. Fig. 8 Chemical structures"/>
  <result pre="known as omacetaxine. This drug displays antitumoral activity in the" exact="treatment" post="of myeloid chronic leukaemia. The mechanism of action implicates"/>
  <result pre="copper chelates which favoured the death of micro-organisms and enabled" exact="treatment" post="of intestinal parasites.305, 306, 307 In 1945, DSF alcohol"/>
  <result pre="discovered accidentally and it was soon used in the clinical" exact="treatment" post="of alcohol dependence.308, 309 DSF is used to treat"/>
  <result pre="that convalescent plasma transfusion benefited patients infected with SARS-CoV-2. Therefore," exact="testing" post="safety and efficacy of transfusing convalescent plasma in patients"/>
  <result pre="genomic perspective and the mechanisms employed in the invasion and" exact="infection" post="of host cells.325 Gao et al.341 promoted the pilot-scale"/>
  <result pre="necessary to safekeep the populationâ€™s health. Hence, before allowing human" exact="testing" post="of COVID-19 vaccines, regulatory organizations must evaluate their safety"/>
  <result pre="They also must demand preclinical evidences that experimental vaccines prevent" exact="infection" post="â€&quot; even if it means waiting weeks or months"/>
  <result pre="for models to become available. This is time well-spent, once" exact="testing" post="vaccines without investing the due amount of time to"/>
  <result pre="useful, and a good part of the literature on the" exact="treatment" post="of COVID-19 so far presents possible alternatives. Hence, this"/>
  <result pre="LPV/RTV, as the most effective drug after various studies, in" exact="isolation" post="or combined therapy, with good results but without a"/>
  <result pre="dependent RNA polymerase (RdRp): a molecular docking studyLife Sci253202011759210.1016/j.lfs.2020.117592 8KandeelM.Al-NazawiM.Virtual" exact="screening" post="and repurposing of FDA approved drugs against COVID-19 main"/>
  <result pre="approved drugs against COVID-19 main proteaseLife Sci251202011762710.1016/j.lfs.2020.117627 9RichardsonP.GriffinI.TuckerC.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet3952020e30e3110.1016/S0140-6736(20)30304-432032529 10ShannonA.LeN.T.T.SeliskoB.Remdesivir and SARS-CoV-2: Structural"/>
  <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyLancet Infect Dis20202056557410.1016/S1473-3099(20)30196-132213337 33KrupovicM.DoljaV.V.KooninE.V.Origin"/>
  <result pre="COVID-19 infection?Lancet Respir Med82020e2110.1016/S2213-2600(20)30116-8 49WangT.DuZ.ZhuF.Comorbidities and multi-organ injuries in the" exact="treatment" post="of COVID-19Lancet3952020e5210.1016/S0140-6736(20)30558-4 50LiX.C.ZhangJ.ZhuoJ.L.The vasoprotective axes of the renin-angiotensin system:"/>
  <result pre="ChinaClin Infect Dis202010.1093/cid/ciaa270[Epub ahead of print] 53Borges do NascimentoI.J.CacicN.AbdulazeemH.M.Novel coronavirus" exact="infection" post="(COVID-19) in humans: a scoping review and meta-analysisJ Clin"/>
  <result pre="injury in COVID-19: management and challengesLancet Gastroenterol Hepatol5202042843010.1016/S2468-1253(20)30057-132145190 59VargaZ.FlammerA.J.SteigerP.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet39520201417141810.1016/S0140-6736(20)30937-532325026 60LiG.FanY.LaiY.Coronavirus infections and immune responsesJ"/>
  <result pre="of murine models after coronavirus infectionJ Virol93201910.1128/JVI.01815-18 72KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
  <result pre="Hypotheses202010.1016/j.mehy.2020.109754 94NobleS.GoaK.L.GemcitabineDrugs54199744747210.2165/00003495-199754030-000099279506 95SchlackK.BoegemannM.SteinestelJ.SchraderA.J.KrabbeL.-M.The safety and efficacy of gemcitabine for the" exact="treatment" post="of bladder cancerExpert Rev Anticancer Ther16201625527110.1586/14737140.2016.114377726781169 96JiangY.HanZ.WangY.HaoW.Depletion of SIRT7"/>
  <result pre="review and meta-analysisGynecol Oncol155201953053710.1016/j.ygyno.2019.09.02631604664 98DyallJ.ColemanC.M.HartB.J.Repurposing of clinically developed drugs for" exact="treatment" post="of middle east respiratory syndrome coronavirus infectionAntimicrob Agents Chemother5820144885489310.1128/AAC.03036-1424841273"/>
  <result pre="Agents Chemother5820144885489310.1128/AAC.03036-1424841273 99SerafinM.B.BottegaA.FolettoV.S.da RosaT.F.HÃ¶rnerA.HÃ¶rnerR.Drug repositioning is an alternative for the" exact="treatment" post="of coronavirus COVID-19Int J Antimicrob Agents55202010596910.1016/j.ijantimicag.2020.105969 100XuJ.CaiJ.ChenJ.An efficient synthesis"/>
  <result pre="broad-spectrum nucleoside analogue BCX4430Nature508201440240510.1038/nature1302724590073 106WestoverJ.B.MathisA.TaylorR.Galidesivir limits Rift Valley fever virus" exact="infection" post="and disease in Syrian golden hamstersAntiviral Res2018156381564510.1016/j.antiviral.2018.05.013 107LiG.De ClercqE.Therapeutic"/>
  <result pre="(2019-nCoV)Nat Rev Drug Discov19202014915010.1038/d41573-020-00016-032127666 108De ClercqE.New nucleoside analogues for the" exact="treatment" post="of hemorrhagic fever virus infectionsChem â€&quot; Asian J1420193962396810.1002/asia.20190084131389664 109ChoyK.-T.WongA.Y.-L.KaewpreedeeP.Remdesivir,"/>
  <result pre="Artmed Editora; 2016. 122OsbornM.Safety and efficacy of telbivudine for the" exact="treatment" post="of chronic hepatitis BTher Clin Risk Manag200978910.2147/TCRM.S531819851526 123ZhaoT.-Q.ZhaoY.-D.LiuX.-Y.Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone"/>
  <result pre="and clinical studiesDiabetes Metab Syndr Clin Res Rev14202064164810.1016/j.dsx.2020.05.018 130ZhaiP.DingY.WuX.LongJ.ZhongY.LiY.The epidemiology," exact="diagnosis" post="and treatment of COVID-19Int J Antimicrob Agents55202010595510.1016/j.ijantimicag.2020.105955 131WarrenT.K.JordanR.LoM.K.Therapeutic efficacy"/>
  <result pre="studiesDiabetes Metab Syndr Clin Res Rev14202064164810.1016/j.dsx.2020.05.018 130ZhaiP.DingY.WuX.LongJ.ZhongY.LiY.The epidemiology, diagnosis and" exact="treatment" post="of COVID-19Int J Antimicrob Agents55202010595510.1016/j.ijantimicag.2020.105955 131WarrenT.K.JordanR.LoM.K.Therapeutic efficacy of the"/>
  <result pre="a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 141MontesinosP.SanzJ.CanteroS.Incidence, risk factors, and outcome of cytomegalovirus" exact="infection" post="and disease in patients receiving prophylaxis with oral valganciclovir"/>
  <result pre="against novel respiratory 2019 coronavirusAntimicrob Agents Chemother202010.1128/AAC.00399-20 157KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in the" exact="treatment" post="of SARS: a new trick for an old drug?CMAJ16820031289129212743076"/>
  <result pre="[Epub ahead of print] 2020. https://doi.org/10.1101/2020.03.17.20037432. 164YanaiH.Favipiravir: a possible pharmaceutical" exact="treatment" post="for COVID-19J Endocrinol Metab102020333410.14740/jem645 165Cai Q, Yang M, Liu"/>
  <result pre="future perspectivesInt J Antimicrob Agents55202010595110.1016/j.ijantimicag.2020.105951 169ChuC.M.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 170ChanJ.F.-W.YaoY.YeungM.-L.Treatment with"/>
  <result pre="findingsThorax59200425225610.1136/thorax.2003.01265814985565 170ChanJ.F.-W.YaoY.YeungM.-L.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
  <result pre="173HungI.F.LungK.C.TsoE.Y.K.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
  <result pre="of ritonavir and lopinavir to wuhan pneumonia coronavirus proteasesBioRxiv202010.1101/2020.01.31.929695 175UyekiT.M.Oseltamivir" exact="treatment" post="of influenza in childrenClin Infect Dis662018150129315362 176TobaiqyM.QashqaryM.Al-DaheryS.Therapeutic management of"/>
  <result pre="molecular docking and binding free energy calculationBioRxiv202010.1101/2020.01.27.921627 182BustiA.J.HallR.G.MargolisD.M.Atazanavir for the" exact="treatment" post="of human immunodeficiency virus infectionPharmacotherapy12200417321747 183MastanS.K.KumarK.E.Influence of atazanavir on"/>
  <result pre="agentsInt J Infect Dis93202026827632081774 204BaronS.A.DevauxC.ColsonP.RaoultD.RolainJ.M.Teicoplanin: an alternative drug for the" exact="treatment" post="of COVID-19?Int J Antimicrob Agents552020105944 205ColsonP.RaoultD.Fighting viruses with antibiotics:"/>
  <result pre="impairmentJ Hepatol63201580581226070406 208GentileI.BuonomoA.R.BorgiaG.Dasabuvir: a non-nucleoside inhibitor of NS5B for the" exact="treatment" post="of hepatitis C virus infectionRev Recent Clin Trials9201411512324882169 209ShahB.PalmiM.SnehaR.In"/>
  <result pre="patient with Crohnâ€™s diseaseInflamm Bowel Dis1220061087108917075351 229Bernal-BelloD.Jaenes-BarriosB.Morales-OrtegaImatinib might constitute a" exact="treatment" post="option for lung involvement in COVID-19Autoimmun Rev19202010256532376403 230SteegmannJ.L.BaccaraniM.BrecciaM.European LeukemiaNet"/>
  <result pre="recommendations for the management and avoidance of adverse events of" exact="treatment" post="in chronic myeloid leukaemiaLeukemia3020161648167127121688 231MughalT.Principal long-term adverse effects of"/>
  <result pre="of host cytokinesCytokine1312020155115 238RossignolJ.F.Nitazoxanide, a new drug candidate for the" exact="treatment" post="of Middle East respiratory syndrome coronavirusJ Infect Public Health9201622723027095301"/>
  <result pre="243RoldanE.Q.BiasiottoG.MagroP.ZanellaI.The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2" exact="infection" post="(COVID-19): a role for iron homeostasis?Pharmacol Res1582020104904 244ThomÃ©R.LopesS.C.P.CostaF.T.M.VerinaudL.Chloroquine: modes"/>
  <result pre="of an undervalued drugImmunol Lett1532013505723891850 245KapoorA.PandurangiU.AroraV.Cardiovascular risks of hydroxychloroquine in" exact="treatment" post="and prophylaxis of COVID-19 patients: a scientific statement from"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov620201632194981 248TouretF.de LamballerieX.Of chloroquine and COVID-19Antiviral Res1772020104762"/>
  <result pre="in vitroCell Discov620201632194981 248TouretF.de LamballerieX.Of chloroquine and COVID-19Antiviral Res1772020104762 249DrakesmithH.PrenticeA.Viral" exact="infection" post="and iron metabolismNat Rev Microbiol6200854155218552864 250DrakesmithH.PrenticeA.M.Hepcidin and the Iron-infection"/>
  <result pre="review on the efficacy and safety of chloroquine for the" exact="treatment" post="of COVID-19J Crit Care57202027928332173110 258SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine in the"/>
  <result pre="treatment of COVID-19J Crit Care57202027928332173110 258SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine in the" exact="treatment" post="of COVID-19 with or without diabetes: a systematic search"/>
  <result pre="SARS-CoV-2 infectionInt J Antimicrob Agents552020105960 260GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
  <result pre="the need for an evidence baseLancet Respir Med8202053954132304640 262RosenbergE.S.DufortE.M.UdoT.Association of" exact="treatment" post="with hydroxychloroquine or azithromycin with in-hospital mortality in patients"/>
  <result pre="Î±/Î²-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathwaysBiol Chem39620151357136726351913 276YavuzS.ÃœnalS.Antiviral" exact="treatment" post="of COVID-19Turkish J Med Sci502020611619 277PatrÃ¬A.FabbrociniG.Hydroxychloroquine and ivermectin: a"/>
  <result pre="new potential synergistic treatmentLife Sci2542020117808 300TangQ.LiS.DuL.Emetine protects mice from enterovirus" exact="infection" post="by inhibiting viral translationAntiviral Res1732020104650 301YangS.XuM.LeeE.M.Emetine inhibits Zika and"/>
  <result pre="mechanisms: inhibiting viral replication and decreasing viral entryCell Discov420183129872540 302ShenL.NiuJ.WangC.High-throughput" exact="screening" post="and identification of potent broad-spectrum inhibitors of coronavirusesJ Virol932019e00023â€&quot;e119"/>
  <result pre="the journey of disulfiram: from an unintended discovery to a" exact="treatment" post="option for alcoholismJ Ment Heal Hum Behav20201541 306KrampeH.EhrenreichH.Supervised disulfiram"/>
  <result pre="target, mechanism of action, and therapeutic potentialRev Med Virol22201221721905149 325XuX.HanM.LiT.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc Natl Acad Sci1172020109701097532350134"/>
  <result pre="for Influenza A (H5N1) InfectionN Engl J Med35720071450145117914053 330HungI.F.N.ToK.K.LeeC.K.Convalescent plasma" exact="treatment" post="reduced mortalityin patients with severe pandemic influenza A (H1N1)"/>
  <result pre="332Mair-JenkinsJ.Saavedra-CamposM.BaillieJ.K.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
 </snippets>
</snippetsTree>
